Kathryn King earned her Ph.D. from the Department of Biochemistry and Molecular Biology at the Victoria University of Manchester in the UK. Following a post-doc in the Department of Medicine at Cambridge University in the UK, she moved to the US FDA. At the FDA she is involved in the product quality (CMC) review of recombinant therapeutic protein products in the Office of Pharmaceutical Quality. She also served as the FDA/CDER topic lead on the ICHQ5A(R2) expert working group.